This site is intended for health professionals only

Genmab regains lymphoma drug rights


Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.

Genmab has regained all rights to the HuMax-CD4

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine